drospirenone · Exeltis Usa Inc · NDA 216285

Drospirenone

Earliest generic entry, as listed
28 Jun 2031

No marketed reference-listed strength; date taken from all listed strengths.

Blocked by patent: US 10179140, US 10603281, US 10849857, US 10987364, US 11123299, US 11291632, US 11291633, US 11351122, US 11413249, US 11439598, US 11478487, US 11504334, US 11951213, US 12090231, US 9603860.

Listed patents · 15 unexpired

PatentClaimsExpires
US 10179140use U-2553 · sets the listed date28 Jun 2031
US 10603281use U-2553 · sets the listed date28 Jun 2031
US 10849857drug product, use U-2553 · sets the listed date28 Jun 2031
US 10987364drug product · sets the listed date28 Jun 2031
US 11123299drug product · sets the listed date28 Jun 2031
US 11291632drug product · sets the listed date28 Jun 2031
US 11291633drug product · sets the listed date28 Jun 2031
US 11351122drug product · sets the listed date28 Jun 2031
US 11413249use U-2553 · sets the listed date28 Jun 2031
US 11439598drug product · sets the listed date28 Jun 2031
US 11478487drug product · sets the listed date28 Jun 2031
US 11504334drug product · sets the listed date28 Jun 2031
US 11951213use U-2553 · sets the listed date28 Jun 2031
US 12090231use U-2553 · sets the listed date28 Jun 2031
US 9603860use U-2553 · sets the listed date28 Jun 2031

Exclusivities · 0 unexpired

No unexpired exclusivities listed.

Paragraph IV certifications · 0

No Paragraph IV certification listed by FDA for this drug.

The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.

Event history

No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.

Products covered · 1

NDA · productFormStrengthListed expiry
216285 · 001 · RLD · discontinuedtablet, chewable, oral3.5MG28 Jun 2031